PAI Partners buys skincare brand Elemis from L'Occitane, ending seven-year hold
What's the deal? PAI PartnersDealroom has a profile for this one. Try Dealroom → has agreed to acquire ElemisDealroom has a profile for this one. Try Dealroom →, a British luxury skincare brand, from L'Occitane GroupDealroom has a profile for this one. Try Dealroom →, the two companies announced on November 4, 2026. Financial terms were not disclosed. The deal is expected to close in the first quarter of 2027, subject to regulatory approvals.
What each side does: Elemis, founded in 1989, builds its range around biotechnology and natural ingredients, led by its Pro-Collagen franchise. PAI Partners is a private equity firm; L'Occitane is a multi-brand beauty group.
The financials: Under seven years of L'Occitane ownership, Elemis nearly doubled net sales, which topped $300 million in its 2026 fiscal year. The US now accounts for roughly half of sales, after several years of double-digit annual growth. Close to half of sales are made online.
Why now? For L'Occitane, the sale is a portfolio move. Chief executive Reinold Geiger called it a "disciplined portfolio decision, focused on long-term value creation for the Group," noting Elemis was the group's first major acquisition, bought for $900 million in 2019.
What's the endgame? PAI plans to reinforce Elemis's UK leadership, accelerate its US rollout, and build out its digital and selective premium retail channels. PAI partners Gaëlle d'Engremont and Colm O'Sullivan called Elemis "a distinctive British brand" with "clinically proven performance" (translated from French).
Noella Gabriel, Elemis chief executive and co-founder, said the brand would "advance Elemis into its next phase of growth with PAI, staying true to our brand, our heritage, and our values" (translated from French).
The signal: The exit shows private equity betting on established, profitable beauty brands over turnaround plays, in a global skincare market estimated at about $170 billion. With no price disclosed, though, the return on an asset L'Occitane bought for $900 million remains impossible to judge.
Read more: finyear.com
Image credit: Generated with Gemini
